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INTRODUCTION
The Androgen Receptor (AR) is a ligand-dependent 
transcription factor and like other members of the Nuclear 
Receptor family, has a modular structure consisting 
of the N-terminal domain, the central DNA-binding 
domain and the C-terminal ligand-binding domain [1]. 
The receptor contains two activation functions (AF), 
the predominant AF-1 in the N-terminus and the weaker 
ligand dependent AF-2 in the ligand binding domain 
(LBD) [2]. In the absence of ligand the receptor is 
localised in the cytoplasm, associated with a heat shock 
protein complex that holds the receptor in a ligand 
binding competent conformation. Upon ligand binding 
the receptor undergoes a conformational change, which 
promotes nuclear localisation, dimerization, recruitment 
of accessory proteins and an intramolecular N-/C-terminal 
interaction [3]. The N-/C-terminal interaction is important 
in reducing ligand off rate and increasing receptor 
stability [4]. The importance of this interaction in AR 
transcriptional activity, however, appears to be promoter 
specific [5, 6].
Coactivators are proteins that bind to and enhance 
the activity of transcription factors while not directly 
binding DNA themselves. Steroid receptor coactivators, 
such as the p160 family, often interact with the AF-2 
surface of agonist-bound nuclear receptors, via an 
α-helical LxxLL motif [7, 8]. However, the AR differs 
from other steroid receptors in that it has greater affinity 
for phenylalanine rich motifs, such as the FQNLF motif 
found in the N-terminus of the AR that mediates the N-/C-
terminal interaction, and those found in coactivators such 
as ARA70 [9-11]. This difference in interaction motif 
preference between steroid receptors is a result of a deeper 
coactivator interaction groove on the surface of the active 
(holo) form of the AR LBD, which can accommodate the 
bulkier phenylalanine residues [10, 12]. Conversely AR, 
like other steroid receptors, can interact with corepressor 
proteins (such as NCoR) in the presence of antagonists, 
which promote a different LBD conformation [13-15]. 
Corepressors bind to the LBD of nuclear receptors at 
a distinct region that nevertheless overlaps with the 
coactivator-interacting region and subsequently inhibit 
transcription of target genes [13, 16].
Prostate cancer growth is almost always dependent 
upon the androgen-signalling axis and as a result, 
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ABSTRACT
Prostate cancer growth is dependent upon the Androgen Receptor (AR) pathway, 
hence therapies for this disease often target this signalling axis. Such therapies 
are successful in the majority of patients but invariably fail after a median of 
2 years and tumours progress to a castrate resistant stage (CRPC). Much evidence 
exists to suggest that the AR remains key to CRPC growth and hence remains a 
valid therapeutic target. Here we describe a novel method to inhibit AR activity, 
consisting of an interaction motif, that binds to the AR ligand-binding domain, fused to 
repression domains. These ‘engineered repressors’ are potent inhibitors of AR activity 
and prostate cancer cell growth and importantly inhibit the AR under circumstances 
in which conventional therapies would be predicted to fail, such as AR mutation and 
altered cofactor levels.
Oncotarget960www.impactjournals.com/oncotarget
androgen deprivation therapy is a common treatment 
option for this disease. This involves one or both of 
chemical castration to ablate circulating androgens and 
antiandrogens – steroidal or non-steroidal ligands that 
bind to the AR LBD but do not promote subsequent 
target gene activation, either due to simple competition, 
by preventing receptor dimerization and/or nuclear 
translocation and DNA-binding, by promoting formation 
of a repressive complex at the androgen response element 
(ARE), or a mixture of mechanisms [15, 17]. Although 
antiandrogens are initially successful in the majority of 
patients, relapse is inevitable and the tumours progress 
to a “castrate resistant” stage (CRPC), for which few 
therapeutic options exist. Much evidence exists to 
suggest that the AR is still driving growth, even in the 
androgen-depleted environment, including frequent 
AR amplification and mutation, as well as alterations 
in cofactor levels and activities [18]. The AR therefore 
remains a valid target for CRPC and novel methods to 
inhibit the AR are required. Ideally such therapies would 
be active even in circumstances where current therapies 
would be predicted to fail (e.g. mutations of the AR 
resulting in broadened ligand preference and promiscuous 
activation [11]).
Due to the limited efficacy of current antiandrogens, 
novel methods to inhibit AR signalling are being devised 
that directly target different regions of the AR. Zhang 
et al., for example, demonstrated that ectopic expression 
of a decoy androgen response element was successful at 
reducing AR activity [19]. Other studies demonstrated 
that targeting either the AF-1 or AF-2 of the AR using 
peptides, can successfully inhibit AR activity [20-22]. 
These consist of specific AR-binding motifs, which 
subsequently block crucial interactions such as the 
N-/C-terminal interaction and recruitment of coactivators. 
Another approach is the engineering of AR-specific 
corepressors. Reeb et al. performed a yeast 2-hybrid 
peptide screen against the full-length AR in the presence 
of the antiandrogen hydroxyflutamide [23]. Fusion of the 
lead interacting peptide with a silencing domain generated 
an AR corepressor with receptor specific inhibitory 
effects.
Here we describe the design and validation of 
AR engineered repressors that combine the desirable 
characteristics of coactivators and corepressors, in 
that they interact with the AR when it is in a holo 
conformation and block its activity. These consist of an 
interaction motif containing an FxxLF motif, fused to 
potent repression domains. Importantly, we demonstrate 
that these factors are successful in inhibiting the AR in 
circumstances thought to lead to castrate resistant prostate 
cancer.
RESULTS
Engineered repressor design
Previous studies have demonstrated that peptides 
designed to target intra- and inter-receptor interactions 
can successfully inhibit AR activity [20, 21]. For example, 
peptides consisting of an FxxLF α-helix, which can bind 
to AF-2 of the AR, inhibit the N-/C-terminal interaction 
and reduce AR activity [21]. In an attempt to make a more 
potent inhibitor of the AR, we fused amino acids 1-54 
of the AR, which contains the 23FQNLF27 motif known 
to interact with the AR LBD (termed the interaction 
motif), to known repression domains from different 
proteins: MAD (amino acids 7-35 [24]), KOX (amino 
acids 1-75 [25]) and PLZF (amino acids 1-452 [26]). The 
resulting constructs are MAD
7-35
-AR
1-54
, KOX
1-75
-AR
1-54
, 
PLZF
1-452
-AR
1-54
 (Figure 1a). These repressors should not 
only sterically disrupt coactivator binding and the N-/C-
terminal interaction, but also bring a potent repression 
domain in close proximity to the receptor upon activation 
by ligand.
The engineered repressors interact with the active 
Androgen Receptor
As proof of principle to confirm that the repressors 
and the AR interact, MAD
7-35
-AR
1-54
 was fused to GFP and 
co-transfected into COS-1 cells with an AR expression 
vector. Confocal microscopy demonstrated that MAD
7-35
-
AR
1-54
 is predominantly nuclear and appears to colocalise 
with the agonist bound AR (Figure 1b), suggesting that 
the proteins interact. This interaction was confirmed 
using co-immunoprecipitation, whereby a GFP antibody 
(against the MAD
7-35
-AR
1-54
 construct) also pulled-down 
full-length AR (Figure 1c). Importantly, this interaction 
was ligand-dependent, as would be expected since the 
interaction of 23FQNLF27 within AR
1-54
 with the AR ligand 
binding domain is dependent upon AF-2 being in an active 
conformation [27].
The engineered repressors inhibit Androgen 
Receptor activity
To investigate the repressive activity of the 
engineered repressors compared to the interaction motif 
and repression domains in isolation, each was transfected 
into COS-1 cells along with an AR expression plasmid 
and an androgen-responsive luciferase reporter gene. 
The N-terminal 54 amino acid fragment of AR expressed 
in isolation reduced AR activity by 34% (Figure 2a). 
Repression domains in isolation had no effect on AR 
activity (Figure 2a, solid lines), but when fused to AR
1-54
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Figure 1: The repressor constructs enter the nucleus and interact with the active androgen receptor. (a) Schematic 
representation of the engineered repressors (not drawn to scale). (b) COS-1 cells were transfected with the AR and GFP-MAD
7-35
-AR
1-54
. 
Cells were fixed following 2hrs of treatment with mibolerone. Confocal microscopy was used to visualise the localisation of GFP-MAD
7-35
-
AR
1-54
 (green) and the full-length AR (stained using ALEXA 594 (red)). Nuclear staining = DAPI (blue). (c) COS-1 cells were transfected 
with the AR and and GFP-MAD
7-35
-AR
1-54
 or GFP-Empty. Cells were treated ± mibolerone for 2hrs and complexes immunoprecipitated 
with an anti-GFP antibody. Immunoprecipitated complexes were separated using SDS-PAGE and immunoblotted for AR (using an antibody 
that does not recognise residues 1-54) and GFP.
the resulting fusion constructs had greater inhibitory action 
than the interaction motif alone: maximal repression for 
AR
1-54
- KOX
1-75
 was 57%, for MAD
7-35
-AR
1-54
 was 81% 
and for PLZF
1-452
-AR
1-54
 was 86% (Figure 2a, broken 
lines). To ensure that this effect was not an artefact of cell 
line used or transiently transfected AR, PC3-WTAR cells 
(PC3 prostate cancer cell line stably expressing AR [28]) 
were transfected with a luciferase reporter and the 
repressors. Similar to the repressive effects demonstrated 
in the COS-1 cell line, the engineered repressors potently 
inhibited AR activity in PC3 cells (Figure 2b).
The interaction domain utilised in the engineered 
repressors contains a phenylalanine rich motif (FQNLF), 
which should be specific for the AR. To investigate if the 
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other closely related steroid receptors (glucocorticoid, 
oestrogen and progesterone receptors) were also inhibited 
by the engineered repressors, transcription assays were 
performed using these receptors. COS-1 cells were 
therefore transfected with plasmids encoding PLZF
1-452
-
AR
1-54
 and the steroid receptors, and cells treated 
with the corresponding ligand. The PLZF
1-452
-AR
1-54
 
repressor weakly inhibited glucocorticoid, oestrogen 
Figure 2: Inhibition of AR activity by the engineered repressors. (a) COS-1 cells were transiently transfected with vectors for 
the AR, TAT-GRE-E1B-LUC, PDM-LACZ-β-GAL and the repressors or interaction motif either in isolation (solid line) or as a fusion 
(broken line). (b) PC3-WTAR were transiently transfected with vectors for TAT-GRE-E1B-LUC, PDM-LACZ-β-GAL, AR
1-54
 or the 
repressors. (c) COS-1 cells were transfected with vectors encoding the androgen, glucocorticoid, oestrogen or progesterone receptors (AR, 
GR, ER, PR), the respective luciferase reporter construct (TAT-GRE-E1B-LUC or ERE-LUC), PDM-LACZ-β-GAL and PLZF
1-452
-AR
1-54
. 
Luciferase activity was normalised with β-galactosidase expression and results expressed as a % of AR activity in the absence of the 
repressors. Mean of 3 independent duplicates ±1SE. T-Test - **p<0.005, ***p<0.0005
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and progesterone receptor activity by <40% compared to 
approximately 80% inhibition of the AR (Figure 2c).
To confirm that both the interaction domain and 
repression domain were required for inhibitory action, 
point mutations were introduced into these domains and 
activity measured using transcription assays. Mutation 
of the FQNLF interaction motif to FQNAA abolished 
repressive activity of MAD
7-35
-AR
1-54
 (Figure 3a). To 
confirm that the repression domain also contributes to 
repressive potential, mutations were introduced in to the 
repression motif of the MAD
7-35
AR
1-54
 vector. Mutation 
of residues L12 and A16 to prolines disrupted intrinsic 
transrepression activity (Supplementary Figure 1 and 
[24]). Fusion of the mutated MAD
7-35
 repression domain 
with AR
1-54
 generated a repressor with markedly weaker 
repressive activity compared to wild-type MAD
7-35
AR
1-54
 
(Figure 3b). We therefore conclude that fusion of an 
interaction motif with a repression domain generates a 
potent repressor of AR activity and that both domains are 
essential for maximal inhibitory potential.
The engineered repressors successfully block 
Androgen Receptor activity in circumstances that 
promote hormone therapy failure
Much evidence exists to suggest that the AR can 
drive CRPC growth. One possible mechanism to explain 
therapy failure leading to CRPC is alterations in levels 
and/or activities of AR co-regulators sensitising the 
pathway to low levels or weakly androgenic ligands. 
Indeed, Gregory et al., demonstrated that the coactivators 
SRC1 (Steroid Receptor Coactivator 1) and TIF2 
(transcriptional intermediary factor 2) were over-expressed 
in the majority of CRPCs [29], and altered expression and 
localisation of AR corepressors in prostate cancer has 
also been described (for example [30-34]). To determine 
whether the engineered repressors can inhibit AR activity 
enhanced by coactivator over-expression, COS1 cells were 
transfected with expression plasmids for the AR, SRC1 
and increasing amounts of engineered repressor. SRC1 
enhanced AR activity by 2.5-fold and the LBD interaction 
Figure 3: The repression domain and interaction motif are both essential for maximal repression of the AR. COS-1 
cells were transiently transfected with vectors for the AR, TAT-GRE-E1B-LUC, PDM-LACZ-β-GAL and MAD
7-35
-AR
1-54
 with wild-type 
or mutated (a) interaction motif (FQNLF to FQNAA) or (b) repression domain (L12P and A16P). Mean ±1SE. T-Test - ** p<0.005, *** 
p<0.0005.
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motif (AR
1-54
) was unable to compete with this enhanced 
activity (Figure 4a). By contrast, the engineered repressors 
were all able to significantly reduce the SRC1-enhanced 
AR activity (Figure 4b-d).
Mutations in the AR gene are rare in the early 
stages of prostate cancer, but their frequency increases 
significantly in advanced stages of the disease [35, 36]. For 
example, Gaddipati et al. found the T877A substitution 
in 25% of metastatic PCa samples analysed [37]. Some 
mutations appear to offer a growth advantage by reducing 
ligand specificity, allowing non-androgen ligands such 
as the antiandrogens cyproterone acetate (CPA) and 
hydroxyflutamide (OHF) to activate the receptor. To 
investigate if the engineered repressors can inhibit 
mutant ARs activated by these antiandrogens, COS-1 
cells were transfected with two AR mutants commonly 
associated with prostate cancer (H874Y and T877A) and 
the engineered repressors. AR mutants H874Y and T877A 
were activated by mibolerone and to a lesser extent by CPA 
and OHF (Figure 5a and b). The engineered repressors 
were considerably more potent inhibitors of these AR 
mutants than AR
1-54
 for all ligand conditions.
Figure 4: The repressors block AR activity enhanced by SRC1. COS-1 cells were transiently transfected with vectors for the 
AR, TAT-GRE-E1B-LUC, PDM-LACZ-β-GAL, SRC1 and (a) AR
1-54
, (b) KOX
1-75
-AR
1-54
, (c) MAD
7-35
-AR
1-54
 or (d) PLZF
1-542
-AR
1-54
. 
Luciferase data was normalised to β-galactosidase expression and expressed as a % of AR activity in the absence of cofactor. Mean ±1SE. 
T-Test - ** p<0.005, *** p<0.0005.
Figure 5: The engineered repressors block mutant ARs activated by androgen and antiandrogens. COS-1 cells were 
transiently transfected with vectors for the (a) H874Y or (b) T877A mutant ARs, TAT-GRE-E1B-LUC, PDM-LACZ-β-GAL and the 
repressors or interaction motif. EtOH – ethanol, MIB - mibolerone, CPA - cyproterone acetate, OHF - hydroxyflutamide. Mean ±1SE. 
T-Test * p<0.05, ** p<0.005, ***p<0.0005.
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The engineered repressors inhibit prostate cancer 
cell growth
We have demonstrated that the engineered 
repressors are potent inhibitors of AR activity and 
inhibit receptor signalling in circumstances that would 
be predicted to promote CRPC. To determine whether 
these inhibitory effects translate into inhibition of prostate 
cancer growth, LNCaP cells were co-transfected with 
plasmids encoding GFP and the engineered repressors, and 
GFP positive cells counted over a time-course (Figure 6 
and Supplementary Figure 2). AR
1-54
 had little effect upon 
Mock 
AR1-54 
Mock 
KOX1-75AR1-54 
Mock 
MAD7-35AR1-54 
Mock 
PLZF1-452AR1-54 
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Figure 6: The engineered repressors significantly reduce prostate cancer proliferation. LNCaP cells were transiently 
co-transfected with vectors for GFP and (a) AR
1-54
, (b) MAD
7-35
AR
1-54
, (c) KOX
1-75
AR
1-54
 or (d) PLZF
1-452
AR
1-54
. GFP positive cells were 
counted 24hrs after transfection (set as day 0), and subsequently counted on days 3 and 7. Automated counting (ImageJ) was performed 
on 10 random fields of view on an Axiovert Fluorescent Microscope (Zeiss), repeated in triplicate and representative figures given. 
(e) LNCaP-C42 cells were transiently transfected with vectors encoding MAD
7-35
-AR
1-54
, KOX
1-75
-AR
1-54
 or Empty and the Zeocin selection 
cassette. Cells were selected with Zeocin for 3 weeks, colonies fixed, stained using crystal violet and colony number quantified. Mean ± 
1SE. T-Test *p<0.05, ** p<0.005, *** p<0.0005.
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proliferation (Figure 6a), whereas the fusion constructs 
all significantly inhibited LNCaP growth within 3 days 
(Figure 6b-d). At day 7, MAD
7-35
-AR
1-54
, KOX
1-75
-AR
1-54
 
and PLZF
1-452
-AR
1-54
 inhibited LNCaP growth by 67, 57 
and 55% respectively.
Colony formation assays were performed using the 
more aggressive LNCaP-C42 prostate cancer cell line [38] 
and the 2 shorter repressors (MAD
7-35
-AR
1-54
, KOX
1-75
-
AR
1-54
). Exogenous expression of MAD
7-35
-AR
1-54
 and 
KOX
1-75
-AR
1-54
 significantly reduced colony formation, 
with no colonies emerging in any experiment using the 
latter construct (Figure 6E).
DISCUSSION
Hormone therapy targeting the AR pathway, is 
a common therapeutic option for the treatment of PCa. 
Although initially successful in the majority of patients, 
such therapies invariably fail after a median of 2 years 
and the tumours progress to the Castrate Resistant (CRPC) 
stage. Few therapeutic options exist for this stage of the 
disease, but much evidence exists to suggest that the AR 
continues to drive CRPC growth, and hence remains a 
valid therapeutic target [39].
Several groups have previously demonstrated 
that peptides designed to bind to regions important in 
AR activity (e.g. Activation Functions 1 and 2) can 
successfully inhibit AR activity [20-23]. We reasoned 
that fusing such peptides to repression domains derived 
from transcriptional repressor proteins would yield more 
potent inhibitors of AR activity. Therefore, we generated 
engineered repressors consisting of an AR LBD interaction 
motif (AR
1-54
), fused to known repression domains from a 
number of potent transcriptional repressors, namely KOX, 
MAD and PLZF [24-26]). These are uniquely designed to 
interact with the AR when it is in an active conformation 
and subsequently block transcriptional activity. Reporter 
assays demonstrated that fusion of the repression domains 
to the AR
1-54
 interaction motif generated potent repressors 
of AR activity. Mutation of the interaction motif (FQNLF 
to FQNAA) completely abolished repression, whereas 
mutation of the MAD
7-35
 repression domain significantly 
reduced, but did not abolish inhibitory potential, likely 
as a result of the intact interaction motif since this alone 
possesses some inhibitory activity ([40] and data herein).
Upon ligand binding, steroid receptors interact 
with coactivators, which enhance transcriptional activity 
[8]. Despite high homology between the LBDs of 
steroid receptors, the AR is idiosyncratic in that it not 
only interacts with α-helical LxxLL motifs present in 
coactivators such as SRC1 but also interacts with, and 
has preference for, similar phenylalanine rich motifs, 
e.g. FxxLF motifs, found in the coactivator ARA70 and 
in the N-terminus of the AR itself [41, 42]. To provide 
AR selectivity of our repressors, we therefore utilised 
an N-terminal fragment of the AR (AR
1-54
) containing 
the 23FQNLF27 motif that mediates the N-/C-terminal 
interaction [42]. The resulting PLZF
1-452
-AR
1-54
 repressor 
was found to be more specific for the AR but did also 
weakly inhibit the other steroid receptors. Previous studies 
using phenylalanine-rich motifs have also found weak 
cross-reactivity with these steroid receptors [21], hence 
refinement of such motifs warrants further investigation.
Multiple mechanisms have been described to explain 
therapy failure and CRPC, including alterations in AR 
cofactor levels/localisation. Transcriptional competition 
assays showed that, while the interaction motif alone was 
unable to compete with the effects of increased SRC1 
expression, all of the engineered repressors were able to 
successfully inhibit AR activity under these conditions.
Mutation of the AR is another mechanism believed 
to contribute to CRPC [35]. Identified mutations in 
prostate cancer cluster in the LBD and several have been 
demonstrated to reduce ligand specificity. For example, 
the prostate cancer associated AR mutations H874Y and 
T877A can be activated by non-androgenic hormones (e.g. 
oestradiol and progesterone) and antiandrogens (e.g. CPA 
and OHF) [11]. Importantly, the engineered repressors were 
able to reduce the activity of these mutants irrespective of 
the activating ligand, successfully blocking the receptors 
when activated by both androgen and anti-androgens.
We have therefore demonstrated that fusion of 
repression domains with an AR-specific interaction motif 
generates potent inhibitors of the AR that are more potent 
than interaction motifs alone, and that these constructs are 
active in circumstances where conventional therapeutics 
would be predicted to fail. Growth assays demonstrated 
that these repressive effects upon the AR do translate to 
growth inhibition of prostate cancer cells. Therefore, the 
use of engineered repressors is a potential therapeutic 
approach to inhibit CRPC, and methods to refine and 
deliver such constructs, for example viral delivery or 
nanoparticles, merit further investigation.
METHODS
Ligands
Mibolerone was purchased from Perkin Elmer 
(MA, USA). Oestradiol, Progesterone, Dexamethasone 
and Cyproterone Acetate were from Sigma Aldrich (MO, 
USA) and Bicalutamide and Hydroxyflutamide from 
Toronto Research Chemicals (Toronto, Canada).
Constructs
Amino acids 1-54 of the AR were PCR amplified 
and cloned into pSG5 using XhoI and BamHI. Repression 
domains from KOX (a.a. 1-75), MAD (a.a. 7-35) and PLZF 
(a.a. 1-452) were subsequently PCR cloned upstream of 
AR
1-54
 using EcoRI and XhoI. To generate the pCDNA4.0 
(Invitrogen, Paisley, UK) engineered repressor constructs, 
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the repressors were PCR cloned into the KpnI and XbaI 
sites. Site directed mutagenesis (QuickChange II, Agilent 
DE, USA) was performed on the pSG5-MAD
7-35
AR
1-54
 
construct to generate constructs with mutation of the 
AR
1-54
 domain (FxxLF to FxxAA) or mutation of the 
repression domain (L12P and A16P). All constructs were 
confirmed by diagnostic digest and sequencing. The 
following plasmids have been previously described: pSG5-
SRC1e [43], pSVAR [44], TAT-GRE-EIB-LUC [45].
Cell Culture
COS1 and LNCaP cells were obtained from 
ATCC and grown at 37°C 5% CO2. COS1 cells 
were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) and LNCaP/LNCaP-C42 cells in Roswell 
Park Memorial Institute (RPMI) medium 1640 (Life 
technologies, Strathclyde, UK), both supplemented with 
2mM L-Glutamine, 100units/ml penicillin, 100mg/ml 
streptomycin (PSG) and 10% foetal bovine serum. PC3-
WTAR cells [28] were grown as above with the addition 
of 4μg/ml of Geneticin (Life Technologies, Gaithersburg, 
MD). For experiments involving hormone manipulation, 
cells were cultured in phenol red free DMEM or RPMI 
supplemented with PSG and 5% charcoal stripped foetal 
bovine serum (stripped medium).
Confocal Microscopy
COS1 cells were plated at 30% confluence on cover 
slips in 24 well plates. Cells were transfected with pSVAR 
and pGFP-MAD
7-35
AR
1-54
 using FuGENE 6 (Promega, WI, 
USA) and incubated for 24hrs before treatment with ligand 
for 2hrs. Wells were washed 3x with PBS and incubated 
in 1% paraformaldehyde for 10 min, washed 3x in PBS 
and incubated for a further 10 min in 0.1% Triton X-100 
in PBS. Wells were again washed 3x with PBS, incubated 
in blocking solution (5% BSA in PBS) for 30 min and a 
further 1 hr with an AR antibody (AR C19, Santa Cruz 
Biotechnology, TX, USA) diluted 1:200 in blocking 
solution. Wells were washed 3x with PBS, re-blocked 
and incubated for 1hr with 594-Alexa Fluor conjugated 
secondary antibody (Invitrogen, Paisley, UK). A final 3x 
PBS washes was performed before the coverslips were 
mounted onto glass slides (Vectorshield containing DAPI, 
DAKO, Cambridge, UK). Images were obtained using a 
Zeiss Confocal Microscope, as previously described [46].
Immunoprecipitation
COS1 cells were seeded at 70% confluence in 
10cm plates in ‘stripped medium’ and transfected with 
plasmids encoding the AR and GFP-MAD
7-35
AR
1-54
 
using FuGENE 6.0 (Promega, WI, USA). Cells were 
left for 24hrs, treated for 2hrs ± 10nM Mibolerone and 
lysed in IP buffer (150mM NaCl, 1% NP-40, 50mM Tris 
pH8.0, 1mM DTT) containing freshly added protease 
inhibitors. Lysates were spun at 13,000 rpm (15 min, 
4°C), supernatants transferred to fresh tubes and protein 
concentration measured using the DC protein assay 
(BioRad, CA, USA). Lysates were pre-cleared with 50 μl 
of sepharose beads (Sigma-Aldrich, MO, USA, 30min 
of rotation at 4°C), supernatant transferred to fresh 
tubes and incubated with anti-GFP antibody (Abcam, 
Cambridge, UK) for 1hr with rotation before addition of 
50 μl of sepharose beads. After 1hr, beads were washed 3 
times with IP buffer, laemmli loading buffer added to the 
beads and samples boiled before protein separation using 
immunoblotting, as previously described [30].
Reporter Assays
COS1 cells were transfected using the calcium 
phosphate method as previously described [11]. Cells 
were seeded in 24 well plates and transfected per well 
with steroid receptor expression plasmids (100 ng), 
pDM-LACZ-β-GAL (100 ng), 1μg TAT-GRE-E1B-
LUC/ERE-LUC (1 µg) and 0-200ng of pSG5-AR
1-54
, 
pSG5-MAD
7-35
-AR
1-54
, KOX
1-75
-AR
1-54
, PLZF
1-452
-AR
1-54
, 
pSG5-MAD
7-35
-AR
1-54
(FQNAA)or pSG5-MAD
7-35
(L12P, 
A16P)-AR
1-54
. PC3-WTAR cells were transfected with 
50ng PDM-LACZ-β-GAL, 250ng TAT-GRE-E1B-LUC 
and 0-200ng of pSG5-AR
1-54
, pSG5-MAD
7-35
-AR
1-54
, 
KOX
1-75
-AR
1-54
, PLZF
1-452
-AR
1-54
 using FuGENE HD 
(Promega, WI, USA) following the manufacturer’s 
instructions. Twenty-four hours after transfection, cells 
were treated with 10nM of ligand and cells incubated 
for a further 16 hrs. Luciferase and β-galactosidase 
expression was measured as previously described [11].
Growth Assays
LNCaP cells were plated to 50% confluence 
in 6 well plates in ‘stripped media’ containing 10nM 
Mibolerone and co-transfected with pGFP-Empty and 
plasmids encoding AR
1-54
, MAD
7-35
-AR
1-54
, KOX
1-75
-AR
1-54
 
or PLZF
1-452
-AR
1-54
 using JetPrime (VWR International 
Ltd., Leicestershire, UK), following the manufacturers 
instructions. 24hrs after transfection (set as day 0), GFP 
positive cells were visualised in 10 random fields of 
view from triplicate wells using an Axiovert Fluorescent 
Microscope (Zeiss, x20 objective) and the number of GFP 
positive cells assessed using Image J (NIH). Subsequent 
cell counting was performed on days 3 and 7.
Colony Formation Assay
Colony formation assays were based on Kawano 
et al. [47]. Briefly, LNCaP-C42 cells were plated in 6 well 
plates and transfected with 2 μg of plasmid using JetPrime 
(VWR International Ltd., Leicestershire, UK). Twenty-
four hours after transfection, cells were trypsinised and 
Oncotarget968www.impactjournals.com/oncotarget
seeded in 10cm dishes. RPMI media containing Zeocin 
(300μg/ml, Invitrogen, Paisley, UK) was changed twice 
weekly and cells grown for 3 weeks, following which 
cells were washed in PBS, fixed and stained in 0.2% 
(w/v) crystal violet, 20% MeOH (10min, RT). Plates were 
washed 6 times in ddH2O and cells counted manually.
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